Johnson & Johnson Medical has acquired German 3D-printed spinal implants maker Emerging Implant Technologies (EIT) for an undisclosed amount.

The EIT portfolio comprises titanium interbody implants for spinal fusion surgery. The products are made using the company’s advanced cellular titanium with an open and interconnected porous structure.

“J&J orthopaedics unit DePuy Synthes will leverage the deal to bolster its interbody implants line, which includes expandable interbody devices and titanium integrated PEEK technology.”

The structure of these implants is designed to facilitate bone growth into the implant. These technologies will be available through the Johnson & Johnson Medical Devices Companies’ commercial infrastructure.

J&J orthopaedics unit DePuy Synthes will leverage the deal to bolster its interbody implants line, which includes expandable interbody devices and titanium integrated PEEK technology.

The EIT technology is set to complement DePuy Synthes’ focus on the interbody implant segment for minimally invasive as well as open spinal surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

DePuy Synthes company group chairman Aldo Denti said: “Our goal is to offer a complete portfolio of interbody solutions that provides surgeons with even more options for the treatment of their patients.

“We are excited to welcome the skilled team at EIT, and together, we aspire to bring to market technologies that allow surgeons to perform spinal fusion procedures reliably and with consistent outcomes.”

The company said that it will continue working on solutions for spinal disease states that have the most potential for both surgeons and patients, such as degenerative disc disease, deformity and complex cervical.

DePuy Synthes will launch a variety of technologies, including interbody implants, minimally invasive spine (MIS), biomaterials and enabling technologies, in the emerging segments within these disease states.